Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Operating Expenses (2024 - 2025)

Historic Operating Expenses for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $26.9 million.

  • Prelude Therapeutics' Operating Expenses fell 2798.05% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year change of. This contributed to the annual value of $146.7 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' Operating Expenses stood at $26.9 million, which was down 2798.05% from $37.8 million recorded in Q4 2024.
  • Over the past 5 years, Prelude Therapeutics' Operating Expenses peaked at $37.8 million during Q4 2024, and registered a low of $26.9 million during Q3 2025.